Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects

J Clin Pharmacol. 2011 Mar;51(3):436-9. doi: 10.1177/0091270010368676. Epub 2010 Apr 23.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
  • Cytochrome P-450 CYP3A Inhibitors*
  • Delayed-Action Preparations
  • Diltiazem / administration & dosage
  • Diltiazem / adverse effects
  • Diltiazem / pharmacology*
  • Drug Interactions
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology*
  • Female
  • Half-Life
  • Humans
  • Hyperlipidemias / drug therapy
  • Linear Models
  • Male
  • Middle Aged
  • Oxazolidinones / adverse effects
  • Oxazolidinones / blood
  • Oxazolidinones / pharmacokinetics*
  • Young Adult

Substances

  • Cholesterol Ester Transfer Proteins
  • Cytochrome P-450 CYP3A Inhibitors
  • Delayed-Action Preparations
  • Enzyme Inhibitors
  • Oxazolidinones
  • Diltiazem
  • anacetrapib